Parkinson's medications and psilocybin.
12 records in this group. None has published human data with psilocybin or another classic psychedelic; the rest draw on each medication's own pharmacology and label. State rules are summarized for Colorado, Oregon and New Mexico.
Also searched as Parkinson's medication · Parkinson medication · parkinsons
01 What the evidence covers
Best evidence available per medication| 12 | No psilocybin data No psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts |
02 Each medication
A to ZParkinson's disease and parkinsonism; Dyskinesia in Parkinson's disease on levodopa (Gocovri)
Not studied with psilocybin. Amantadine can cause hallucinations and confusion, so added effects on perception are possible.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Parkinsonism (add-on treatment); Drug-induced movement side effects (extrapyramidal disorders, except tardive dyskinesia)
It can cause heat intolerance, fast heart rate, confusion and visual hallucinations, which may overlap with psilocybin's effects.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Parkinson's disease; Post-encephalitic parkinsonism
Levodopa raises brain dopamine, and its effect on psilocybin is unknown. Also, its label reports hallucinations with dopamine-boosting medicines.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Parkinson's disease "off" episodes (add-on to levodopa/carbidopa)
Its label reports hallucinations, which may add to psilocybin's perceptual effects (not studied with psilocybin).
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Parkinson's disease "off" episodes (add-on to levodopa/carbidopa)
Its target enzyme plays no reported role in clearing psilocybin. Also, its label reports sudden sleep, low blood pressure and hallucinations.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Parkinson's disease; Restless legs syndrome (moderate to severe)
Not studied with psilocybin; its label reports hallucinations, so added perceptual effects are possible. Stopping it suddenly after regular use can cause withdrawal.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Parkinson's disease
Not studied with psilocybin; it mainly blocks one enzyme (MAO-B) at usual doses. Also, its label warns of serotonin syndrome with antidepressants.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Parkinson's disease; Restless legs syndrome (moderate to severe)
Its label reports hallucinations, which may add to psilocybin's perceptual effects. Also, it can cause sudden sleep episodes and dizziness on standing.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Parkinson's disease "off" episodes (add-on to levodopa/carbidopa)
Not studied with psilocybin; it mainly blocks one enzyme (MAO-B). Its label warns of high blood pressure and serotonin syndrome with serotonin-boosting drugs.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Parkinson's disease (add-on to levodopa/carbidopa); Major depressive disorder in adults (Emsam patch)
Not studied with psilocybin; usual oral doses mainly block one enzyme (MAO-B), but the patch or higher doses may raise psilocybin levels and blood pressure.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Parkinson's disease in adults
Not studied with psilocybin; its label reports hallucinations, so added perceptual effects are possible. It can also lower blood pressure.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
- TrihexyphenidylEvidence: No psilocybin data
Parkinsonism, as add-on therapy; Drug-induced movement side effects (extrapyramidal symptoms)
Its acetylcholine-blocking effects may add to psilocybin's: faster heart rate, less sweating and more risk of confusion or delirium.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
03 Properties the records flag
Records with each flag| 12 | Psychiatric reactions |
| 8 | Sedating or CNS depressant |
| 8 | Withdrawal or rebound if stopped abruptly |
| 7 | Lowers blood pressure or causes orthostasis |
| 5 | Raises blood pressure or heart rate |
| 3 | Anticholinergic |
| 3 | MAO inhibition |
| 3 | Serotonergic |
| 2 | Lowers seizure threshold or carries seizure risk |
Flags describe a medication's own properties, each cited in its record. A flag is not a finding about any combination. Definitions are on the Method page.
04 State rules
Official text governsNo provision names these medications or this group.
Rule 2.2(A)(9): a facilitator must tell prospective participants in writing that anyone taking a psychotropic medication identified as a risk factor on the safety screen must meet one of the 2.2(A)(7) conditions. 3 of the 12 medications in this group are psychotropic; the rule applies when one is identified as a risk factor on a participant's screen.
No provision names these medications or this group.
Rules not final; the proposed rules reviewed name no medication in this group.
05 Studies cited in this group
Records citing eachRelated classes
- MAO inhibitors3 shared
Records reviewed 2026-10-03 to 2026-11-02. Each row summarizes one record; the full record, with every source, opens in the browser and is not sent to the server. All classes · Browse A–Z